TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02373930
Drug: DTG/RPV 50 mg/25 mg: Product Code AQ
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
Study: NCT02373930
Drug: DTG/RPV 50 mg/25 mg: Product Code AK
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTG/RPV will be supplied as pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
Study: NCT02373930
Drug: DTG/RPV 50 mg/25 mg: Product Code AR
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
Study: NCT02537860
Drug: Intravenous (IV) fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will be given 1 μg/kg intravenous (IV) fentanyl as premedication
Study: NCT01922843
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03486236
Drug: Matched Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebos matched to VX-440, TEZ, and IVA.
Study: NCT03361501
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 x 1 g capsules administered orally once daily for 26 weeks
Study: NCT03139370
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously
Study: NCT01998646
Drug: ASP4058
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT01998646
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT01910844
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Metronomic cyclophosphamide per os 150 mg from day 1 to day 14 - total dose 2100 mg every 3 weeks
Study: NCT00817414
Drug: LCI699-matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCI699-matching placebo oral capsules
Study: NCT00817414
Drug: LCI699
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCI699 oral capsules
Study: NCT04562324
Drug: SSRI or SNRI or benzodiazepines or tricyclic antidepressants or other antidepressants or antipsychotics or other sedative-hypnotics
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medications to relieve anxiety
Study: NCT01358500
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous infusion using STANPUMP
Study: NCT02015819
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT00981435
Drug: Prednisolone 1%
Normalized name: GENTAMICIN 0.3/PREDNISOLONE 1% OPH SUSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 1% to lasered eye 4 times/day for 4.5 days
Study: NCT00981435
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac 0.5% to lasered eye 4 times/day for 4.5 days
Study: NCT00466505
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg po BID starting on day 1 and continuing until progressive disease, excessive toxicity or removal from study for other reasons listed in the protocol.
Study: NCT03752905
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline control
Study: NCT00002523
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002523
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00827489
Drug: HTC-867
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03563534
Drug: Glass Ionomer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Margins of cavitated lesion(s) will be excavated.The carious teeth will be isolated, kept dry, apply resin modified glass ionomer.
Study: NCT00628810
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00628810
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02910778
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive placebo once daily for 14 days (until study day 15). On study day 15, placebo in combination with a loading dose of 180 mg ticagrelor will be administered.
Study: NCT01412437
Drug: sapropterin dihydrochloride
Normalized name: Sapropterin Dihydrochloride
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 20 mg/kg for 4 months
Study: NCT01412437
Drug: sapropterin dihydrochloride
Normalized name: Sapropterin Dihydrochloride
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00831051
Drug: Q8003
Normalized name: POUCH,DRAINABLE,NEW IMAGE H#18003
Approvals — FDA: no, EMA: no, PMDA: no
Description: One Q8003 (morphine sulfate and oxycodone HCl) 12mg/8mg IR Capsule q6h
Study: NCT00831051
Drug: Q8003
Normalized name: POUCH,DRAINABLE,NEW IMAGE H#18003
Approvals — FDA: no, EMA: no, PMDA: no
Description: One Q8003 (morphine sulfate and oxycodone HCl) 6mg/4mg IR Capsule q6h
Study: NCT03659435
Drug: RID-TDS 9.5 mg/24 h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 consecutive applications of 1 patch (1st patch for 4 days, 2nd patch for 3 days, 3rd patch for 4 days) covering an 11-day period
Study: NCT03659435
Drug: Exelon® 9.5 mg/24 h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11 consecutive applications of 1 patch (each patch will be applied for 1 day) covering an 11-day period
Study: NCT00847613
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo tablets administered BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
Study: NCT00847613
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets administered at 5 mg BID daily through the end of the study during the double-blind, active-extension period.
Study: NCT00847613
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets administered at 10 mg BID daily through the end of the study during the double-blind, active-extension period.
Study: NCT00040534
Drug: Farnesyl Protein Transferase Inhibitor
Normalized name: farnesyl acetate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00396578
Drug: aerosolized vancomycin or gentamicin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00561353
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules identical in appearance to TMC435 capsules taken orally (by mouth) once daily for 28 days.
Study: NCT01273818
Drug: Gentamicin and cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 mg topically, intra-operative,single dose and intravenous 1000 mg cefazolin 1 hour before operation
Study: NCT01273818
Drug: Gentamicin
Normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 mg gentamicin application intraoperatively
Study: NCT03180762
Drug: JNJ-64140284 0.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of JNJ-64140284 will be administered as an oral solution.
Study: NCT03180762
Drug: JNJ-64140284 2.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg of JNJ-64140284 will be administered as an oral solution.
Study: NCT03180762
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered.
Study: NCT00772395
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given once weekly start on 2nd postoperative day for 26 weeks (6 months)
Study: NCT04432428
Drug: Sufentanil Sublingual Tablet
Normalized name: SUFentanil Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: all patients will receive tablets for sublingual use, containing 15 microgram of sufentanil. The sufentanil tablets come in a cartridge (40 tablets) and are administered with a special patient-controlled device that uses thumb tag recognition.~max dose per hour : 3 tablets of 15µg sufentanil
Study: NCT01815684
Drug: ASP3652
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT01815684
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT00640822
Drug: Calcipotriol plus hydrocortisone ointment vehicle
Normalized name: hydrocortisone Rectal Ointment [Hemorrodil Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily application for up to 8 weeks
Study: NCT00640822
Drug: Calcipotriol plus hydrocortisone ointment
Normalized name: hydrocortisone Rectal Cream [Recort Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily application for up to 8 weeks
Study: NCT03368235
Drug: AZD9567
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral OD SGRM administered as suspension
Study: NCT03368235
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral capsules of 20 mg prednisolone administered OD for two weeks
Study: NCT01697345
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03426046
Drug: Pulp Capping Agents
Normalized name: acai fruit pulp
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biocompatible materials
Study: NCT03520049
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04407234
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen administered orally.
Study: NCT01515046
Drug: Gemcitabine with escalating ascorbic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1000 mg/m2 weekly for 3 weeks with one week off (this is 1 cycle)~Ascorbate dose is targeted to achieve plasma level of 350 mg/dL. Infusions are given twice weekly, each week of a cycle (4 weeks to a cycle)
Study: NCT04025203
Drug: Ibuprofen Arginine
Normalized name: ibuprofen arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT04099732
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablet
Study: NCT04485884
Drug: IN-C005 dose A
Approvals — FDA: no, EMA: no, PMDA: no
Description: One time dose of IN-C005 dose A taken orally.
Study: NCT04485884
Drug: IN-C005 dose B
Approvals — FDA: no, EMA: no, PMDA: no
Description: One time dose of IN-C005 dose B taken orally.
Study: NCT04485884
Drug: IN-C005 dose C
Approvals — FDA: no, EMA: no, PMDA: no
Description: One time dose of IN-C005 dose C taken orally.
Study: NCT04485884
Drug: IN-C005 dose F
Normalized name: F
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of IN-C005 dose F once daily for 7 days.
Study: NCT01731093
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00504244
Drug: continuation of azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine 2 mg/kg
Study: NCT00277017
Drug: 5-Flourouracil, Interferon-a, IL-2 and Thalidomide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive oral dosages of Thalidomide at 200mg/day to start, with dosage gradually increasing up to a max of 1200mg/day. This will be taken in combination with:5-fluorouracil, given by continuous IV infusion over 24 hours (Day 1) every week for 4 weeks.~Interferon-α, given subcutaneously on Day 1, 3 and 5 of every week for 4 weeks. Interleukin-2, given by continuous IV infusion Days 2-5, every week for 4 weeks.~Treatment will be followed by 2 weeks of rest then repeated.
Study: NCT01762761
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03017508
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: a sublingual tablet identical to the active drug will be given before performing an anxiety provoking speech task. Participants will then be clinically assessed every hour for three hours.
Study: NCT03224468
Drug: Medical Marijuana
Normalized name: Picea mariana resin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this group can choose when, where, and how much medical marijuana to use.
Study: NCT01381107
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual administration once daily for 7 consecutive days.
Study: NCT00618956
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00705900
Drug: LCD
Normalized name: MGlcDAG (1->2) glucosyltransferase
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 applications / day for 12 weeks
Study: NCT03296189
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mls normal saline
Study: NCT01038921
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 8 mg dose of Melatonin
Study: NCT01038921
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01465334
Drug: High-Dose Methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00422539
Drug: 70% trichloroacetic acid
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01918332
Drug: Rosuvastatin 20mg
Normalized name: ROSUVASTATIN 20MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01918332
Drug: Rosuvastatin 20mg placebo
Normalized name: rosuvastatin 20 MG
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00536952
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 2.5 mL ampules (2.5 mg) will be nebulized and inhaled once daily using a recommended nebulizer
Study: NCT00946907
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3000mg/day of aspirin during the 4th first days and 2000mg/day of placebo during the 17th following days
Study: NCT00843986
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premix bag
Study: NCT03697239
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25, 37.5, 56.25 or 75 grams/m2
Study: NCT03206658
Drug: Spironolactone 25 mg
Normalized name: spironolactone 25 MG
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A dose of 25 mg of spironolactone will be administered orally or through the nasogastric /nasoenteral tube to the patients every 24 hours, at 8-9 am.
Study: NCT03206658
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: The contents of a placebo capsule will be administered orally or through the nasogastric / nasoenteral tube to the patients every 24 hours, at 8-9 am.
Study: NCT00509886
Drug: Drysol
Normalized name: Drysol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% aluminum chloride hexahydrate
Study: NCT00509886
Drug: Drioff
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% aluminum acetate
Study: NCT04680884
Drug: Experimental for steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg/day of IV methylprednisolone for three days. As of day 4, the daily dose will be tapered to 1 mg/kg/day until day 7, followed by 0,5 mg/kg/day from day 8 to day 14 + IV placebo of isavuconazole
Study: NCT03951987
Drug: 4 ml CG5503
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml of the CG5503 infusion solution corresponding to 40 mg CG5503 (tapentadol hydrochloride).
Study: NCT01284192
Drug: ASP3026
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT00825071
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml, intravenously
Study: NCT04438655
Drug: Oral antibiotic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotic drugs:~- Bimixin (Neomicin + Bacitracin tablet) 25000 UI + 2500 UI: h. 8-16-24 the day before surgery if the procedure takes place in the morning; h. 16-24-8 if the procedure takes place in the afternoon.
Study: NCT02514538
Drug: Non- effervescent Paracetamol kern
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1g
Study: NCT02514538
Drug: Effervescent paracetamol termalgin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g
Study: NCT00181298
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dispensing initially 5 mg. Dose Increased by 5 mg weekly to 20 mg/d final dose by week 4
Study: NCT02799381
Drug: Optimized antiparkinsonian treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose levels of prescribed antiparkinsonian medications were individually optimized to their maximum therapeutic effect.
Study: NCT02799381
Drug: Levodopa-Carbidopa Intestinal Gel (LCIG)
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose levels were individually optimized.
Study: NCT04079777
Drug: Clinical treatment
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid Resuscitation, Anti-infection
Study: NCT02525172
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02638012
Drug: Floseal
Normalized name: Floseal Hemostatic Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine spray (2%) is then administered using 1-2 sprays in the affected nasal cavity via the nostril that is to have Floseal® applied. Once the bleeding has stopped following application of the Floseal® a 50 cc syringe with sterile saline will be used to irrigate the treated nasal cavity to remove any excess Floseal® product as per manufacturer recommendations. This is done with the patient's head tilted downwards at a 30 degree angle so that the irrigation and excess product is removed from the nasal cavity. Once the irrigation is complete, the nasal cavity is inspected for evidence of continued bleeding.
Study: NCT01712360
Drug: NAFT500 (pediatric)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied to both feet and groin area
Study: NCT01712360
Drug: NAFT600 (pediatric)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied to both feet only
Study: NCT01712360
Drug: NAFT500 (adult)
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Applied to both feet and groin area
Study: NCT01712360
Drug: NAFT600 (adult)
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Applied to both feet
Study: NCT02574221
Drug: cavity protection toothpaste
Normalized name: Aquafresh Cavity Protection Toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.243% sodium fluoride toothpaste
Study: NCT01568944
Drug: Oral Antibiotic and Oral Rinse
Normalized name: beclometasone and antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO Amoxicillin in 500 mg / Metronidazole 250 mg of each TID for 8 days plus 2 ounces of 0.12% chlorhexidine mouthrinse used BID
Study: NCT01691118
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00101361
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive an identically appearing placebo capsule until full healing occurs or for 24 weeks, which ever comes first.
Study: NCT02061995
Drug: PREOB® Intravenous Infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient will undergo a single intravenous administration of PREOB®.
Study: NCT02935738
Drug: Prednisolone treatment
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infertile men were treated with prednisolone tablet, which is an intermediate acting corticosteroid, po, for 21 days of their wife's menstrual cycles. Briefly, the prednisolone regimen was started with a dose of 5mg, tid, for two weeks followed by 5mg bid for five days. This was further tapered to one tablet of 5mg/day for two days. Patients were then given one week of rest from the treatment, before this prednisolone regimen was repeated for another two cycles.
Study: NCT03864276
Drug: inhalation (desflurane) group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthesia is induced and maintained with desflurane and sufentanil
Study: NCT03864276
Drug: total intravenous (propofol) anesthesia
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthesia is induced and maintained with propofol and sufentanil
Study: NCT01923064
Drug: Lauromacrogol
Normalized name: Lauromacrogol
Approvals — FDA: no, EMA: no, PMDA: no
Description: endoscopic injection of lauromacrogol + cyanoacrylate + lauromacrogol for gastric varices
Study: NCT04146558
Drug: Individualized internal ayurvedic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: All possible internal preparations will be administered for a period of 12 months.~All administered preparations with its dosage and duration will be documented All preparations will be subjected to lab test for clearing heavy metal and pesticide content before the administration
Study: NCT03669133
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo daily
Study: NCT02660944
Drug: RSLV-132
Approvals — FDA: no, EMA: no, PMDA: no
Description: RNase-Fc fusion protein
Study: NCT02660944
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo
Study: NCT03898934
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo for the same period
Study: NCT01844076
Drug: Quinacrine and Capecitabine
Normalized name: quinacrine
DrugBank: Quinacrine (DB01103)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Phase I portion of the study will aim to determine the tolerability of both agents in combinations when used at established clinical doses. This portion of the study will more closely resemble a pilot study or feasibility study rather than a dose escalation.
Study: NCT05839561
Drug: MTX as monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX in a single dose of 100 mg intravenously on day 0
Study: NCT01400828
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: (encapsulated) Tablets QD/14 days
Study: NCT02286960
Drug: Steroid
Normalized name: Steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: A short 4 day course is administered to the first group of patients with voice disorders before the initiation of voice therapy.
Study: NCT01050777
Drug: Liposomal Paromomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal form of 10% Paromomycin